VEGFR2/CD309 Antikörper (Extracellular Domain) (Biotin)

Produktnummer ABIN155178

Produktdetails anti-VEGFR2/CD309 Antikörper (Biotin)

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Bindungsspezifität: Extracellular Domain

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser VEGFR2/CD309 Antikörper ist konjugiert mit Biotin

Applikation: Western Blotting (WB), Immunofluorescence (IF), Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro)), Enzyme Immunoassay (EIA)

Spezifität: The Unconjugated Monoclonal antibody will detect native Human VEGFR-2/KDR in ELISA experiments and on the surface of different Human cell types.

Aufreinigung: Affinity Chromatography on Protein G

Immunogen: Recombinant Human soluble extracellular KDR (D7) (110 kDa) protein (Cat.-No AR26018PUN)

Klon: 4 (20I6)

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Flow cytometry: 2-5 μg/mL. Immunoflourescence. Immunohistochemistry on frozen sections. ELISA. Western blot.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Rekonstitution: Restore in sterile water to a concentration of 0.1-1.0 mg/mL

Buffer: PBS, 0.02 % Sodium Azide, BSA (50x)

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Prior to reconstitution store at 2-8 °C. Following reconstitution store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Details zu VEGFR2/CD309

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Andere Bezeichnung: CD309 / VEGFR-2 / Flk-1 (VEGFR2 Produkte)

Synonyme: CD309 antikoerper, FLK1 antikoerper, VEGFR antikoerper, VEGFR2 antikoerper, 6130401C07 antikoerper, Flk-1 antikoerper, Flk1 antikoerper, Krd-1 antikoerper, Ly73 antikoerper, VEGFR-2 antikoerper, sVEGFR-2 antikoerper, Vegfr-2 antikoerper, FLK-1 antikoerper, flk-1 antikoerper, vegfr-2 antikoerper, KDR antikoerper, FLK/KDR antikoerper, flk1 antikoerper, flk1b antikoerper, kdrb antikoerper, si:busm1-205d10.1 antikoerper, si:ch211-254j6.1 antikoerper, si:ch211-278f21.4 antikoerper, wu:fc31a09 antikoerper, fk52c05 antikoerper, flk antikoerper, kdr antikoerper, kdra antikoerper, vegfr2 antikoerper, vegfr4 antikoerper, vegr2 antikoerper, wu:fk52c05 antikoerper, kinase insert domain receptor antikoerper, kinase insert domain protein receptor antikoerper, vascular endothelial growth factor receptor kdr-like antikoerper, kinase insert domain receptor (a type III receptor tyrosine kinase) antikoerper, kinase insert domain receptor like antikoerper, KDR antikoerper, Kdr antikoerper, LOC100136647 antikoerper, kdr antikoerper, kdrl antikoerper

Hintergrund: VEGF receptor 2 is a member of a receptor tyrosine kinase family whose activation plays an essential role in a large number of biological processes such as embryonic development, wound healing, cell proliferation, migration and differentiation. Like other growth factor receptors, upon ligand binding VEGF receptor 2 dimerises and is autophosphorylated on multiple tyrosine residues. These sites can be involved in the regulation of kinase activity or serve as binding sites for SH2 and phosphotyrosine binding containing signalling proteins. Phosphorylation of Tyrosines 1054 and 1059 in the activation loop is required for activation of VEGF receptor 2 and its intrinsic tyrosine kinase activity. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.Synonyms: FLK1, KDR, Kinase NYK, Kinase insert domain receptor, Protein-tyrosine kinase receptor Flk-1, VEGF Receptor 2, VEGFR2, Vascular endothelial growth factor receptor 2

Gen-ID: 3791

NCBI Accession: NP_002244

UniProt: P35968

Pathways: RTK Signalweg, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling